Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat

Behavioural Pharmacology

Volumn 19, Issue 2, 2008, Pages 121-128

  Davoodi, Nima ^a   Kalinichev, Mikhail ^b   Clifton, Peter G ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antipsychotic; Appetite; Histamine; Olanzapine; Rat; Schizophrenia; Side effect; Thioperamide; Weight gain; Ziprasidone

Indexed keywords

HISTAMINE; HISTAMINE H1 RECEPTOR; OLANZAPINE; THIOPERAMIDE; ZIPRASIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APPETITE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEEDING BEHAVIOR; HYPOPHAGIA; MALE; NEUROTRANSMISSION; NONHUMAN; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; APPETITE; BENZODIAZEPINES; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FAT EMULSIONS, INTRAVENOUS; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HISTAMINE H3 ANTAGONISTS; HYPOTHALAMUS; MALE; NEURONS; PIPERAZINES; PIPERIDINES; RATS; SYNAPTIC TRANSMISSION; TASTE; THIAZOLES;

EID: 40549098407     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3282f62c66     Document Type: Article

References (56)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
2. Assie MB, Dominguez H, Consul-Denjean N, Newman-Tancredi A (2006). In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn Schmiedebergs Arch Pharmacol 373:441-450.
3. Attoub S, Moizo L, Sobhani I, Laigneau JP, Lewin MJ, Bado A (2001). The H3 receptor is involved in cholecystokinin inhibition of food intake in rats. Life Sci 69:469-478.
4. Bryden KE, Kopala LC (1999). Body mass index increase of 58% associated with olanzapine. Am J Psychiatry 156:1835-1836.
5. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, et al. (1999). Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 37:107-122.
6. Casey DE, Zorn SH (2001). The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 62 (Suppl 7):4-10.
7. Choi S, DiSilvio B, Unangst J, Fernstrom JD (2007). Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci 81:1024-1030.
8. Clifton PG, Rusk IN, Cooper SJ (1989). Stimulation and inhibition of food intake by the selective dopamine D2 agonist, N-0437: a meal pattern analysis. Pharmacol Biochem Behav 33:21-26.
9. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005). A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181:80-89.
10. Cooper SJ, Al-Naser HA, Clifton PG (2006). The anorectic effect of the selective dopamine D1-receptor agonist A-77636 determined by meal pattern analysis in free-feeding rats. Eur J Pharmacol 532:253-257.
11. Cope MB, Nagy TR, Fernandez JR, Geary N, Casey DE, Allison DB (2005). Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes (Lond) 29:607-614.
12. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999). Ziprasidone 80 and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20:491-505.
13. Davis JD (1973). The effectiveness of some sugars in stimulating licking behavior in the rat. Physiol Behav 11:39-45.
14. Davis JD, Smith GP (1992). Analysis of the microstructure of the rhythmic tongue movements of rats ingesting maltose and sucrose solutions. Behav Neurosci 106:217-228.
15. Fell MJ, Marshall KM, Williams J, Neill JC (2004). Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol 18:149-155.
16. Fell MJ, Gibson R, McDermott E, Sisodia G, Marshall KM, Neill JC (2005a). Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. Behav Brain Res 160:338-343.
17. Fell MJ, Neill JC, Rao C, Marshall KM (2005b). Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats. Psychopharmacology (Berl) 182:499-507.
18. Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, Vickers S, et al. (2007). The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berl) 194:221-231.
19. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, et al. (2002). Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159:1055-1057.
20. Goudie AJ, Smith JA, Halford JC (2002). Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol 16:291-296.
21. Hartfield AW (2003). DPhil thesis: effects of atypical antipsychotics on feeding and drinking in rats: towards a model of obesity associated with antipsychotic drug treatment Experimental Psychology. University of Sussex. pp. 1-382.
22. Hartfield AW, Moore NA, Clifton PG (2003a). Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology (Berl) 167:115-122.
23. Hartfield AW, Moore NA, Clifton PG (2003b). Serotonergic and histaminergic mechanisms involved in intralipid drinking? Pharmacol Biochem Behav 76:251-258.
24. Hartfield AW, Moore NA, Clifton PG (2006). Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats. Neuropsychopharmacology 31:1938-1945.
25. Hills MJ, Reynolds GP (2007). 5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity. Brain Res 1149: 14-17.
26. Jansen FP, Mochizuki T, Yamamoto Y, Timmerman H, Yamatodani A (1998). In vivo modulation of rat hypothalamic histamine release by the histamine H3 receptor ligands, immepip and clobenpropit. Effects of intrahypothalamic and peripheral application. Eur J Pharmacol 362:149-155.
27. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DN (2005). Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs. olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology (Berl) 182:220-231.
28. Kalinichev M, Rourke C, Jones DN (2006). Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone vs. olanzapine. Behav Pharmacol 17:289-292.
29. Kaur G, Kulkarni SK (2002). Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiatry 26:277-285.
30. Kirk SL, Neill JC, Jones DN, Reynolds GP (2004). Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur J Pharmacol 505:253-254.
31. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526.
32. Lee MD, Clifton PG (1992). Partial reversal of fluoxetine anorexia by the 5-HT antagonist metergoline. Psychopharmacology (Berl) 107:359-364.
33. Leurs R, Blandina P, Tedford C, Timmerman H (1998). Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci 19:177-183.
34. Ligneau X, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, et al. (1998). Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 287:658-666.
35. Lin JS, Sakai K, Vanni-Mercier G, Arrang JM, Garbarg M, Schwartz JC, Jouvet M (1990). Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 523:325-330.
36. Minet-Ringuet J, Even PC, Lacroix M, Tome D, de Beaurepaire R (2006). A model for antipsychotic-induced obesity in the male rat. Psychopharmacology (Berl) 187:447-454.
37. Mochizuki T, Yamatodani A, Okakura K, Takemura M, Inagaki N,Wada H (1991). In vivo release of neuronal histamine in the hypothalamus of rats measured by microdialysis. Naunyn Schmiedebergs Arch Pharmacol 343:190-195.
38. Mollet A, Lutz TA, Meier S, Riediger T, Rushing PA, Scharrer E (2001). Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am J Physiol Regul Integr Comp Physiol 281:R1442-R1448.
39. Morimoto T, Yamamoto Y, Yamatodani A (2001). Brain histamine and feeding behavior. Behav Brain Res 124:145-150.
40. Ookuma K, Sakata T, Fukagawa K, Yoshimatsu H, Kurokawa M, Machidori H, Fujimoto K, (1993). Neuronal histamine in the hypothalamus suppresses food intake in rats. Brain Res 628:235-242.
41. Orsetti M, Ghi P, Di Carlo G (2001). Histamine H(3)-receptor antagonism improves memory retention and reverses the cognitive deficit induced by scopolamine in a two-trial place recognition task. Behav Brain Res 124: 235-242.
42. Pouzet B, Mow T, Kreilgaard M, Velschow S (2003). Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 75:133-140.
43. Prast H, Tran MH, Fischer H, Kraus M, Lamberti C, Grass K, Philippu A (1999). Histaminergic neurons modulate acetylcholine release in the ventral striatum: role of H3 histamine receptors. Naunyn Schmiedebergs Arch Pharmacol 360:558-564.
44. Reynolds GP, Zhang Z, Zhang X (2003). Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 160:677-679.
45. Schlicker E, Betz R, Gothert M (1988). Histamine H3 receptor-mediated inhibition of serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 337:588-590.
46. Schlicker E, Fink K, Detzner M, Gothert M (1993). Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J Neural Transm Gen Sect 93:1-10.
47. Schlicker E, Werthwein S, Zentner J (1999). Histamine H3 receptor-mediated inhibition of noradrenaline release in the human brain. Fundam Clin Pharmacol 13:120-122.
48. Schmidt AW, Lebel LA Jr, Howard HR, Zorn SH (2001). Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425:197-201.
49. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73.
50. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M (1991). Histaminergic transmission in the mammalian brain. Physiol Rev 71:1-51.
51. Spector AC, Klumpp PA, Kaplan JM (1998). Analytical issues in the evaluation of food deprivation and sucrose concentration effects on the microstructure of licking behavior in the rat. Behav Neurosci 112:678-694.
52. Stahl SM, Shayegan DK (2003). The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 64 (Suppl 19):6-12.
53. Theisen FM, Cichon S, Linden A, Martin M, Remschmidt H, Hebebrand J (2001). Clozapine and weight gain. Am J Psychiatry 158:816.
54. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S (2007). Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci 80:1635-1640.
55. Vestri HS, Maianu L, Moellering DR, Garvey WT (2007). Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 32:765-772.
56. Ward BO, Somerville EM, Clifton PG (2000). Intraaccumbens baclofen selectively enhances feeding behavior in the rat. Physiol Behav 68: 463-468.